Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors

Biochemistry

Volumn 49, Issue 38, 2010, Pages 8376-8387

  Pandey, Krishan K ^a   Bera, Sibes ^a   Vora, Ajaykumar C ^a   Grandgenett, Duane P ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GENES; INTEGRATION; VIRUSES;

AGAROSE GEL; BINDING INHIBITORS; BINDING POCKETS; DNA BINDING; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1; IN-VITRO; INHIBITORY MECHANISM; INTEGRASE; NANOMOLAR CONCENTRATION; PHYSICAL TRAPPING; STRUCTURAL CLASS; SYNAPTIC COMPLEX; TIME-DEPENDENT; VIRAL DNA; VIRUS REPLICATION; WILD TYPES;

DISEASES;

AGAROSE; ELVITEGRAVIR; INTEGRASE INHIBITOR; MK 2048; RALTEGRAVIR; RDS 1997; RDS 2197; UNCLASSIFIED DRUG; VIRUS DNA; 2 PYRROLIDONE DERIVATIVE; INTEGRASE; QUINOLONE DERIVATIVE;

ARTICLE; CROSS RESISTANCE; DNA BINDING; DRUG DNA INTERACTION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GEL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; VIRUS REPLICATION; WILD TYPE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DNA, VIRAL; HIV-1; HUMANS; INTEGRASE INHIBITORS; INTEGRASES; MUTATION; PYRROLIDINONES; QUINOLONES; VIRUS REPLICATION;

EID: 77957096837     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi100514s     Document Type: Article

References (56)

1. Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., Jones, P., Kinzel, O., Laufer, R., Monteagudo, E., Muraglia, E., Nizi, E., Orvieto, F., Pace, P., Pescatore, G., Scarpelli, R., Stillmock, K., Witmer, M. V., and Rowley, M. (2008) Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection J. Med. Chem. 51, 5843-5855
2. Markowitz, M., Morales-Ramirez, J. O., Nguyen, B. Y., Kovacs, C. M., Steigbigel, R. T., Cooper, D. A., Liporace, R., Schwartz, R., Isaacs, R., Gilde, L. R., Wenning, L., Zhao, J., and Teppler, H. (2006) Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals J. Acquired Immune Defic. Syndr. 43, 509-515
3. Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B. Y., and Teppler, H. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection N. Engl. J. Med. 359, 339-354
4. Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., Barnard, R. J., Miller, M. D., DiNubile, M. J., Nguyen, B. Y., Leavitt, R., and Sklar, P. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374, 796-806
5. Ceccherini-Silberstein, F., Malet, I., D'Arrigo, R., Antinori, A., Marcelin, A. G., and Perno, C. F. (2009) Characterization and structural analysis of HIV-1 integrase conservation AIDS Rev. 11, 17-29
6. Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Teppler, H., and Nguyen, B. Y. (2008) Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection N. Engl. J. Med. 359, 355-365
7. Fransen, S., Gupta, S., Danovich, R., Hazuda, D., Miller, M., Witmer, M., Petropoulos, C. J., and Huang, W. (2009) Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred by multiple non-overlapping genetic pathways J. Virol. 83, 11440-11446
8. Fransen, S., Karmochkine, M., Huang, W., Weiss, L., Petropoulos, C. J., and Charpentier, C. (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure Antimicrob. Agents Chemother. 53, 4522-4524
9. Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., and Hertogs, K. (2008) Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors J. Virol. 82, 10366-10374
10. McColl, D. J., Fransen, S., Gupta, S., Parkin, N., Margot, N., Chuck, S., Cheng, A. K., and Miller, M. D. (2007) Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS 9137), in XVI International Drug Resistance Workshop, p S11, Barbados, West Indies.
11. Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., and Matsuoka, M. (2008) Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) J. Virol. 82, 764-774
12. Wirden, M., Simon, A., Schneider, L., Tubiana, R., Malet, I., Ait-Mohand, H., Peytavin, G., Katlama, C., Calvez, V., and Marcelin, A. G. (2009) Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug J. Antimicrob. Chemother. 64, 1087-1090
13. Pandey, K. K., Bera, S., Zahm, J., Vora, A., Stillmock, K., Hazuda, D., and Grandgenett, D. P. (2007) Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate J. Virol. 81, 12189-12199
14. Li, M., Mizuuchi, M., Burke, T. R., Jr., and Craigie, R. (2006) Retroviral DNA integration: reaction pathway and critical intermediates EMBO J. 25, 1295-1304
15. Bera, S., Pandey, K. K., Vora, A. C., and Grandgenett, D. P. (2009) Molecular interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration J. Mol. Biol. 389, 183-198
16. Pandey, K. K. and Grandgenett, D. P. (2008) HIV-1 integrase strand transfer inhibitors: novel insights into their mechanism of action Retrovirol.: Res. Treatment 2, 11-16
17. Pandey, K. K., Sinha, S., and Grandgenett, D. P. (2007) Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration J. Virol. 81, 3969-3979
18. Li, M. and Craigie, R. (2009) Nucleoprotein complex intermediates in HIV-1 integration Methods 47, 237-242
19. Faure, A., Calmels, C., Desjobert, C., Castroviejo, M., Caumont-Sarcos, A., Tarrago-Litvak, L., Litvak, S., and Parissi, V. (2005) HIV-1 integrase crosslinked oligomers are active in vitro Nucleic Acids Res. 33, 977-986
20. Hare, S., Gupta, S. S., Valkov, E., Engelman, A., and Cherepanov, P. (2010) Retroviral intasome assembly and inhibition of DNA strand transfer Nature 464, 232-236
21. Hazuda, D. J., Anthony, N. J., Gomez, R. P., Jolly, S. M., Wai, J. S., Zhuang, L., Fisher, T. E., Embrey, M., Guare, J. P., Jr., Egbertson, M. S., Vacca, J. P., Huff, J. R., Felock, P. J., Witmer, M. V., Stillmock, K. A., Danovich, R., Grobler, J., Miller, M. D., Espeseth, A. S., Jin, L., Chen, I. W., Lin, J. H., Kassahun, K., Ellis, J. D., Wong, B. K., Xu, W., Pearson, P. G., Schleif, W. A., Cortese, R., Emini, E., Summa, V., Holloway, M. K., and Young, S. D. (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase Proc. Natl. Acad. Sci. U.S.A. 101, 11233-11238
22. Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., and Miller, M. D. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 287, 646-650
23. Witmer, M. and Danovich, R. (2009) Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses Methods 47, 277-282
24. Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A. G., Subra, F., Deprez, E., and Mouscadet, J. F. (2009) The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation Nucleic Acids Res. 37, 1193-1201
25. Cherepanov, P., Surratt, D., Toelen, J., Pluymers, W., Griffith, J., De Clercq, E., and Debyser, Z. (1999) Activity of recombinant HIV-1 integrase on mini-HIV DNA Nucleic Acids Res. 27, 2202-2210
26. Sinha, S., Pursley, M. H., and Grandgenett, D. P. (2002) Efficient concerted integration by recombinant human immunodeficiency virus type 1 integrase without cellular or viral cofactors J. Virol. 76, 3105-3113
27. Grandgenett, D. P., Bera, S., Pandey, K. K., Vora, A. C., Zahm, J., and Sinha, S. (2009) Biochemical and biophysical analyses of concerted (U5/U3) integration Methods 47, 229-236
28. Vacca, J., Wai, J., Fisher, T., Embrey, M., Hazuda, D., Miller, M., Felock, P., Witmer, M., Gabryelski, L., and Lyle, T. (2007) Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors, in 4 th International AIDS Society (IAS) Conference, July 22-25, 2007, Sydney, Australia.
29. Wai, J., Fisher, T., Embrey, M., Egbertson, M., Vacca, J., Hazuda, D., Miller, M., Witmer, L., Gabryelski, L., and Lyle, T. (2007) Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles, in 14 th Conference on Retroviruses and Opportunistic Infections, Feb 25-28, 2007, Los Angeles, CA.
30. Sato, M., Motomura, T., Aramaki, H., Matsuda, T., Yamashita, M., Ito, Y., Kawakami, H., Matsuzaki, Y., Watanabe, W., Yamataka, K., Ikeda, S., Kodama, E., Matsuoka, M., and Shinkai, H. (2006) Novel HIV-1 integrase inhibitors derived from quinolone antibiotics J. Med. Chem. 49, 1506-1508
31. Di Santo, R., Costi, R., Roux, A., Artico, M., Lavecchia, A., Marinelli, L., Novellino, E., Palmisano, L., Andreotti, M., Amici, R., Galluzzo, C. M., Nencioni, L., Palamara, A. T., Pommier, Y., and Marchand, C. (2006) Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action J. Med. Chem. 49, 1939-1945
32. Di Santo, R., Costi, R., Roux, A., Miele, G., Crucitti, G. C., Iacovo, A., Rosi, F., Lavecchia, A., Marinelli, L., Di Giovanni, C., Novellino, E., Palmisano, L., Andreotti, M., Amici, R., Galluzzo, C. M., Nencioni, L., Palamara, A. T., Pommier, Y., and Marchand, C. (2008) Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities J. Med. Chem. 51, 4744-4750
33. Sinha, S. and Grandgenett, D. P. (2005) Recombinant HIV-1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells J. Virol. 79, 8208-8216
34. Chen, X., Tsiang, M., Yu, F., Hung, M., Jones, G. S., Zeynalzadegan, A., Qi, X., Jin, H., Kim, C. U., Swaminathan, S., and Chen, J. M. (2008) Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors J. Mol. Biol. 380, 504-519
35. Svarovskaia, E. S., Barr, R., Zhang, X., Pais, G. C., Marchand, C., Pommier, Y., Burke, T. R., Jr., and Pathak, V. K. (2004) Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions J. Virol. 78, 3210-3222
36. Goffinet, C., Allespach, I., Oberbremer, L., Golden, P. L., Foster, S. A., Johns, B. A., Weatherhead, J. G., Novick, S. J., Chiswell, K. E., Garvey, E. P., and Keppler, O. T. (2009) Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo J. Virol. 83, 7706-7717
37. Delelis, O., Thierry, S., Subra, F., Simon, F., Malet, I., Alloui, C., Sayon, S., Calvez, V., Deprez, E., Marcelin, A. G., Tchertanov, L., and Mouscadet, J. F. (2010) Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo Antimicrob. Agents Chemother. 54, 491-501
38. Grandgenett, D. P., Inman, R. B., Vora, A. C., and Fitzgerald, M. L. (1993) Comparison of DNA binding and integration half-site selection by avian myeloblastosis virus integrase J. Virol. 67, 2628-2636
39. Zahm, J. A., Bera, S., Pandey, K. K., Vora, A., Stillmock, K., Hazuda, D., and Grandgenett, D. P. (2008) Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance Antimicrob. Agents Chemother. 52, 3358-3368
40. Chen, H., Wei, S. Q., and Engelman, A. (1999) Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome J. Biol. Chem. 274, 17358-17364
41. Garvey, E. P., Schwartz, B., Gartland, M. J., Lang, S., Halsey, W., Sathe, G., Carter, H. L., and Weaver, K. L. (2009) Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant Biochemistry 48, 1644-1653
42. Langley, D. R., Samanta, H. K., Lin, Z., Walker, M. A., Krystal, M. R., and Dicker, I. B. (2008) The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors Biochemistry 47, 13481-13488
43. Copeland, R. A. (2005) Slow binding inhibitors, in Evaluation of enzyme inhibitors in drug discovery (Copeland, R. A., Ed.) pp 141 - 177, Wiley-Interscience, New York.
44. Johnson, A. A., Santos, W., Pais, G. C., Marchand, C., Amin, R., Burke, T. R., Jr., Verdine, G., and Pommier, Y. (2006) HIV-1 integration requires the viral DNA end (5′-C) interaction with glutamine 148 of the integrase flexible loop J. Biol. Chem. 281, 461-467
45. Marinello, J., Marchand, C., Mott, B. T., Bain, A., Thomas, C. J., and Pommier, Y. (2008) Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants Biochemistry 47, 9345-9354
46. Pommier, Y., Johnson, A. A., and Marchand, C. (2005) Integrase inhibitors to treat HIV/AIDS Nat. Rev. Drug Discov. 4, 236-248
47. Pommier, Y. and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions Curr. Med. Chem. Anticancer Agents 5, 421-429
48. Dicker, I. B., Terry, B., Lin, Z., Li, Z., Bollini, S., Samanta, H. K., Gali, V., Walker, M. A., and Krystal, M. R. (2008) Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors J. Biol. Chem. 283, 23599-23609
49. Malet, I., Delelis, O., Valantin, M. A., Montes, B., Soulie, C., Wirden, M., Tchertanova, L., Peytavin, G., Reynes, J., Mouscadet, J. F., Katlama, C., Calvez, V., and Marcelin, A. G. (2008) Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob. Agents Chemother. 52, 1351-1358
50. Mouscadet, J. F., Arora, R., Andre, J., Lambry, J. C., Delelis, O., Malet, I., Marcelin, A. G., Calvez, V., and Tchertanov, L. (2009) HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations J. Mol. Recognit. 22, 480-494
51. Mouscadet, J. F., Delelis, O., Marcelin, A. G., and Tchertanov, L. (2010) Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist. Update (in press).
52. Metifiot, M., Maddali, K., Naumova, A., Zhang, X., Marchand, C., and Pommier, Y. (2010) Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir Biochemistry 49, 3715-3722
53. Grobler, J. A., McKemma, P. M., and Ly, S., and (2009) Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, in 10th International Workshop on Clinical Pharmacology of HIV Therapy, pp Abstract O - 10, Amsterdam.
54. Engelman, A. and Cherepanov, P. (2008) The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication PLoS Pathog. 4, e1000046
55. Hare, S. and Cherepanov, P. (2009) The interaction between lentiviral integrase and LEDGF: structural and functional insights Viruses 1, 780-801
56. Kessl, J., McKee, C., Eidahl, J., Shkriabai, N., Katz, A., and Kvaratskhelia, M. (2009) HIV-1 integrase-DNA recognition mechanisms Viruses 1, 713-736